Afaq Ahmad
Hematology & Oncology · Uniontown, PANPI 1801933965
Payments from drug & device makers
Across 27 payments — averaging $106.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AstraZeneca$270
- CSL Behring$198
- ADC Therapeutics America, Inc.$125
- Eisai Inc.$124
- Amgen$95
- plus $115 from 3 others
What the payments were for
- Consulting fees$1,76862%
- Speaking & faculty fees$1505%
- Food & beverage$63722%
- Education$30911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 6 | $1,937 |
| AstraZeneca(2 entities) | 2 | $270 |
| CSL Behring | 13 | $198 |
| ADC Therapeutics America, Inc. | 1 | $125 |
| Eisai Inc. | 1 | $124 |
| Amgen | 1 | $95 |
| Seagen Inc. | 1 | $90 |
| Acrotech Biopharma Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,863 in reported general payments places this provider in the 40th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 26 | $407,667 |
| XtandiEnzalutamide | 30 | $336,970 |
| OjjaaraMomelotinib Dihydrochloride | 11 | $315,534 |
| Lenalidomide | 16 | $192,345 |
| Imatinib Mesylate | 38 | $72,397 |
| Abiraterone Acetate | 28 | $39,501 |
| EliquisApixaban | 49 | $33,556 |
| Xtampza ErOxycodone Myristate | 15 | $16,383 |
| LinzessLinaclotide | 12 | $6,412 |
| Anastrozole | 131 | $4,070 |
| Hydroxyurea | 32 | $1,582 |
| Prochlorperazine Maleate | 60 | $1,129 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 39 | $606 |
| Dexamethasone | 36 | $605 |
| Oxycodone Hcl | 39 | $503 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Uniontown
- Diwakar DavarPittsburgh$21.6M
- Jason LukePittsburgh$15M
- Stephen BagleyPhiladelphia$13.1M
- Leonard ApplemanPittsburgh$12.8M
- Jing Zhou HouPittsburgh$11.9M
- Taofeek OwonikokoPittsburgh$9.7M
- Stephen SchusterPhiladelphia$9.5M
- Pooja GhataliaPhiladelphia$8.3M
- Corey LangerPhiladelphia$7.7M
- Alfred GarfallPhiladelphia$7.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.